Vor Biopharma Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $321.5M | $93.3M | $94.3M | $64.5M | $47.5M |
| Operating expenses | $371.6M | $121.2M | $126.0M | $93.4M | $69.0M |
| Operating income | -$371.6M | -$121.2M | -$126.0M | -$93.4M | -$69.0M |
| Net income | -$696.0M | -$116.9M | -$117.9M | -$92.1M | -$68.9M |
| Balance Sheet | |||||
| Cash and equivalents | $396.5M | $81.9M | $31.4M | $57.7M | $119.8M |
| Current assets | $458.1M | $96.5M | $140.8M | $236.9M | $214.4M |
| Total assets | $464.1M | $142.9M | $198.1M | $299.4M | $242.6M |
| Current liabilities | $25.2M | $18.6M | $15.6M | $13.1M | $10.2M |
| Total liabilities | $628.4M | $46.2M | $47.4M | $48.8M | $26.3M |
| Stockholders' equity | -$164.3M | $96.7M | $150.7M | $250.6M | $216.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$142.7M | -$99.7M | -$100.3M | -$85.1M | -$69.1M |
| Depreciation and amortization | $2.9M | $3.5M | $3.5M | $2.5M | $1.4M |
| Stock-based compensation | $18.9M | $9.8M | $13.4M | $10.7M | $4.3M |
| Capital expenditure | $941,000 | $229,000 | $1.1M | $8.5M | $3.9M |
| Free cash flow | -$143.7M | -$99.9M | -$101.4M | -$93.6M | -$73.0M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Impairments | $0 | $0 | $0 | $0 | — |
Shares outstanding 54.2M · Free float 30.0%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.